利妥昔单抗联合化疗治疗小细胞淋巴瘤/慢性淋巴细胞白血病的疗效分析

Efficacy of Rituximab Combined with Chemotherapy in the Treatment of Small Cell Lymphoma/Chronic Lymphocytic Leukemia

目的分析利妥昔单抗联合化疗治疗小细胞淋巴瘤/慢性淋巴细胞白血病(SLL/CLL)的临床效果。方法选取南阳市中心医院2016年1月—2018年5月间接受诊治的SLL/CLL患者126例按随机数字表法分为两组,每组63例。对照组选择常规化疗,观察组在对照组基础上给予利妥昔单抗治疗。分别比较两组患者治疗后临床治疗效果,并观察其用药过程中有无不良反应事件发生。结果 (1)治疗后,观察组患者治疗总有效率明显优于对照组;(2)观察组患者不良反应发生率(7.93%)显著低于对照组(25.39%)(χ2=6.914,P=0.009)。结论小细胞淋巴瘤/慢性淋巴细胞白血病患者应用利妥昔单抗联合化疗治疗效果更佳,同时也减少了不良反应,安全性较好,值得在临床推广应用。

Objective To analyze the clinical effect of rituximab combined with chemotherapy in the treatment of small cell lymphoma/chronic lymphoblastic leukemia(SLL/CLL).Methods 126 SLL/CLL patients from January,2016 to May,2018 were randomly divided into two groups,with 63 cases in each group.The control group were treated with conventional chemotherapy,and the observation group were treated with rituximab on the basis of the control group.The clinical effects of two groups of patients after treatment were compared,and whether there were adverse events in the course of treatment was observed.Results(1)After treatment,the effective rate of observed was significantly better than that of the control group(.2)The incidence of adverse reactions in the observation group(7.93%)was significantly lower than that in the control group(25.39%)(χ2=6.914%,P=0.009).Conclusion Rituximab combined with chemotherapy in patients with small cell lymphoma/chronic lymphoblastic leukemia is more effective and can reduce the adverse reactions.It is safe and worth popularizing in clinical practice.